Ragtime for acetylsalicylic acid in vascular neurology

E.A. Shirokov

Moscow branch of S.M. Kirov Military Medical Academy

Cerebrovascular diseases are one of the most common causes of death, falling life expectancy and persistent disability. Thus, the most significant problems of modern medicine is improving the effectiveness of the preventive measures for stroke. Acetylsalicylic acid (ASA)
is the antiplatelet therapy gold standard in vascular neurology. The article shows the ASA leading role in the first vascular event prevention in patients with high cardiovascular risk. The personification treatment methods, based on the analysis of the cranial ultrasound screening results and laboratory tests are discussed. Conclusions about the need for the ASA use at the early stages of disease during the manifestation of the first symptoms were drawn on the basis of the current clinical guidelines analysis and the latest publications on the acute ischemic stroke problem. The ASA efficacy and safety in the ea rly secondary prevention of stroke and other thrombotic complications were confirmed.

The article also contains new data on dual antiplatelet therapy after a stroke. The data, published in recent years, on the ASA low efficacy in primary stroke prevention does not eliminate the need for antiplatelet therapy in high-risk patients. Cardiovascular risk stratification is a necessary condition for the safe and justified use of antiplatelet drugs to prevent the first vascular event.

Keywords: ischemic stroke, stroke prevention, antiplatelet agents, antiplatelet therapy, cardiovascular risk, acetylsalicylic acid, Sanovasc.

For citation: Shirokov E.A. Ragtime for acetylsalicylic acid in vascular neurology. RMJ. 2019;4:22–27.